Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Effective inhibitory activity against MCF-7, A549 and HepG2 cancer cells by a phosphomolybdate based hybrid solid

Author affiliations

Abstract

A novel Strandberg type polyoxomolybdate based organic–inorganic hybrid solid, [{4,4′-H2bpy}{4,4′-Hbpy}2{H2P2Mo5O23}]·5H2O (1) has been synthesized and structurally characterized by the single crystal X-ray diffraction technique. The structure consists of a discrete type phosphomolybdate cluster, [H2P2Mo5O23]4−, connected with three protonated 4,4′-bipyridine molecules by strong hydrogen bonding interactions. The In vitro anti-tumoral activity of compound (1) was tested against human breast cancer (MCF-7), human lung cancer (A549) and human liver cancer (HepG2) cells. The Strandberg type cluster was used against the MCF-7 and A549 cancer cells for the first time hitherto. It shows considerable inhibitory effect with IC50 values of 33.79 μmol L−1, 25.17 μmol L−1, and 32.11 μmol L−1 against HepG2, A549 and MCF-7 respectively. The anti-tumoral activity of 1 was also found to be comparable with that of a routinely used chemotherapeutic agent, methotrexate (MTX), with an IC50 value of 42.03 μmol L−1 for HepG2, 26.93 μmol L−1 for A549 and 49.79 μmol L−1 for MCF-7. The anti-proliferation activity is mediated by the arrest of the A549 and HepG2 cells in the S phase and MCF-7 in the G2/M phase of the cell cycle as suggested by flow cytometry. Results suggest that apoptosis and necrosis pathways ultimately lead to the death of the cancer cells.

Graphical abstract: Effective inhibitory activity against MCF-7, A549 and HepG2 cancer cells by a phosphomolybdate based hybrid solid

Back to tab navigation

Supplementary files

Article information


Submitted
19 Mar 2020
Accepted
30 Apr 2020
First published
30 Apr 2020

Dalton Trans., 2020, Advance Article
Article type
Paper

Effective inhibitory activity against MCF-7, A549 and HepG2 cancer cells by a phosphomolybdate based hybrid solid

A. Joshi, R. Gupta, B. Singh, D. Sharma and M. Singh, Dalton Trans., 2020, Advance Article , DOI: 10.1039/D0DT01042A

Social activity

Search articles by author

Spotlight

Advertisements